JMB2302
/ Shanghai Jeyou Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
JMB2302, a novel MUC16×CD3 bispecific T cell engager, demonstrates potent antitumor activity in lung adenocarcinoma and ovarian cancer models and a favorable safety profile in cynomolgus monkeys
(SITC 2026)
- No abstract available
Bispecific • Clinical • Preclinical • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1